GIPR and Parkinson disease: Subsequent studies then showed that GIPR agonism has neuroprotective effects in mouse models for Alzheimer's and Parkinson's disease [[926], [927], [928], [929]], ameliorates drug-induced emesis [[930], [931], [932]], and decreases body weight in rodents through centrally-mediated inhibition of food intake [581,795] (Figure 8).